Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas. Show more

Location: 1017 Ranch Road 620 South, Lakeway, TX, 78734, United States | Website: https://www.anebulo.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

95.73M

52 Wk Range

$0.80 - $3.42

Previous Close

$2.33

Open

$2.38

Volume

6,216

Day Range

$2.23 - $2.38

Enterprise Value

86.98M

Cash

11.63M

Avg Qtr Burn

-1.587M

Insider Ownership

40.54%

Institutional Own.

54.99%

Qtr Updated

06/30/25